No Data
Medrx Sees FY Loss Y846.00M
Medrx: Summary of Financial Results for the 3rd Quarter Ending 2024/12 [Japanese GAAP] (Consolidated)
Morinaga Milk, mcdonald's, Toyo Suisan, Eisai (8th) (1429-5463)
※Please note that the above calendar is tentative and subject to change based on the company's convenience. --------------------------------------- November 8th (Fri) <1429> Japan Aqua <1435> RoboHome <143A> Ishin <1450> Tanaka Construction Industry <1451> KHC <1518> Mitsui Matsushima HD <151A> Dai <167A> Ryo
Emerging markets stocks digest: Fulta continues to rise significantly, sea U sea hits the daily limit.
<4598> DELTA-P 533 +47 surged significantly. After the trading on the 28th, the progress of the phase 1/2 clinical trial of DFP-10917 and VEN was announced, which is considered a positive development. DFP-10917, when given as a low-dose continuous infusion, is believed to be highly safe, stops cancer cells in the G2/M phase, and induces apoptosis (programmed cell death). Therefore, a strong synergistic effect can be expected when combined with VEN (a BCL-2 inhibitor). Currently, a phase 1 clinical trial is underway.
Hot stocks digest (morning session): Sakura, LITALICO, Flutta, etc.
Stocks hit the daily limit. The company announced its semi-annual financial results the day before, with operating profit reaching 1.3 billion yen, a 5.2-fold increase compared to the same period last year, surpassing the upward revised figure of 1.1 billion yen on September 20th.
Medrek -- Initiates clinical trials of transdermal patch "MRX-7MLL" containing memantine for Alzheimer's treatment.
Rising. The company's 100% subsidiary in australia has announced the start of clinical trials for the MRX-7MLL (memantine patch, Alzheimer's treatment drug) under development, which is considered a positive development. In this clinical trial (P1a), the aim is to confirm the percutaneous absorption and safety of MRX-7MLL in healthy individuals (especially safety on the skin). In order to obtain approval for the new drug, demonstrating biological equivalence with memantine oral tablets could prove the effectiveness of MRX-7MLL.